Q1 2025 Myriad Genetics Inc Earnings Call Transcript
Key Points
- Myriad Genetics Inc (MYGN) reported strong performance in its prenatal testing segment, with revenue growth of 11% year-over-year.
- The company saw a 10% year-over-year volume growth in its ForeSight and Prequel tests.
- Myriad Genetics Inc (MYGN) expanded its gross margins by 50 basis points, achieving a 59% gross margin due to lab efficiencies.
- The company is on track to launch its first AI-enabled Prolaris test by the end of the year, which is expected to support clinical decisions at the time of biopsy.
- Myriad Genetics Inc (MYGN) is making progress on its new product pipeline, including the upcoming launch of the combined carrier screening and NIPS assay, and the PRECISE MRD test.
- The company reported a 3% year-over-year decline in total revenue for the first quarter, with GeneSight and myRisk tests underperforming.
- Revenue from GeneSight was down 20% year-over-year, primarily due to UnitedHealthcare's coverage policy change.
- Myriad Genetics Inc (MYGN) reduced its 2025 annual revenue guidance by $35 million and adjusted operating expenses by $25 million.
- The company faced challenges with EMR integrations, which have been slower than expected, impacting the hereditary cancer testing volumes.
- There is a significant headwind from the UnitedHealthcare policy change, resulting in a $10 million revenue impact in the first quarter.
Good day, and thank you for standing by. Welcome to the Myriad Genetics first quarter 2025 financial earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Matt Scalo, Senior Vice President of Investor Relations.
Please go ahead.
Good afternoon, and welcome to the Myriad Genetics first quarter 2025 earnings call. During the call, we will review the financial results we released today. And afterwards, we will host a Q&A session. Our quarterly earnings release was issued this afternoon on Form 8-K and can be found on our website at investor.merid.com. I'm Matt Scalo, Senior Vice President of Investor Relations, on the call with me today are Sam Raha, our President and Chief Executive Officer; Scott Leffler, our Chief Financial Officer; and Mark Verratti, our Chief Operating Officer.
This call can be heard live via webcast at investor
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
